Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA

Elizabeth Wehler (), Natalie Boytsov, Claudia Nicolay, Oscar Herrera-Restrepo and Stacey Kowal
Additional contact information
Elizabeth Wehler: IQVIA
Natalie Boytsov: Eli Lilly and Company, Lilly Corporate Center
Claudia Nicolay: Lilly Deutschland GmbH
Oscar Herrera-Restrepo: IQVIA
Stacey Kowal: IQVIA

PharmacoEconomics, 2020, vol. 38, issue 1, No 11, 123-123

Abstract: Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-019-00857-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:38:y:2020:i:1:d:10.1007_s40273-019-00857-7

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-019-00857-7

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().